NASDAQ:MDVN (MDVN) (MDVN) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free MDVN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$81.44▼$81.4450-Day Range N/A52-Week Range$26.41▼$81.48VolumeN/AAverage Volume3.55 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (MDVN) alerts: Email Address Ad Porter & CompanyTruth about Trump you’ve never heardEverything about Donald Trump is public. Every part of his life has been dragged out in the media. But there’s one story I bet you’ve never heard about Trump. For the full story, click here. About (MDVN) Stock (NASDAQ:MDVN)Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.Read More Ad Porter & CompanyTruth about Trump you’ve never heardEverything about Donald Trump is public. Every part of his life has been dragged out in the media. But there’s one story I bet you’ve never heard about Trump. For the full story, click here. MDVN Stock News HeadlinesMarch 27, 2024 | nasdaq.comNotable ETF Outflow Detected - HYLBJanuary 28, 2024 | msn.comNearly a thousand take chilly plunge off Oak Street Beach for annual fundraiserMay 1, 2024 | Porter & Company (Ad)#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. January 8, 2024 | msn.comPackers beat Bears 17-9 to clinch playoff spot, head to DallasDecember 30, 2023 | msn.comGoogle agrees to settle $5-B lawsuit over ‘incognito’ modeDecember 29, 2023 | msn.comKanye West and Wife Bianca Censori Will Have a 'Fiery' Start to 2024, Psychic PredictsSeptember 2, 2023 | thestreet.comMedivation Alzheimer's Drug Fails Pivotal StudyJune 26, 2023 | thestreet.comMedivation (MDVN) Stock Falling After Earnings Estimates CutMay 1, 2024 | Porter & Company (Ad)#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. June 26, 2023 | thestreet.comMedivation (MDVN) Stock Falling After Earnings Estimates CutJune 13, 2023 | morningstar.comCore Medalist ETFsMay 31, 2023 | bbc.co.ukThe Connor Phillips ShowApril 21, 2023 | thestreet.comIncyte (INCY) Stock Rises on Takeover Speculation After $14 Billion Pfizer, Medivation DealApril 21, 2023 | thestreet.comMedivation Stock Hits New 52-Week High (MDVN)April 1, 2023 | msn.comMavs Lose to Heat, Play-In Hopes Continue to Take Major HitsMarch 8, 2023 | msn.comMillie Bobby Brown is 'ready to leave Stranger ThingsJanuary 26, 2023 | msn.comLake Nacogdoches notches its first 2023 Legacy ShareLunkerJanuary 15, 2023 | msn.comEx-Huddersfield Town boss Danny Cowley pens emotional goodbye message to Portsmouth supportersDecember 29, 2022 | msn.comGoody’s Name Creates Another Addams Family Wednesday MysteryDecember 25, 2022 | thestreet.comMedivation (MDVN) Stock Surges, Will Explore SaleOctober 18, 2022 | finance.yahoo.comJupiter Wellness’s Potential New OTC Drug Could Put Some More Joy Back Into Breast Cancer Survivors’ Lives - Yahoo FinanceOctober 10, 2022 | msn.comNBC played the 'That’s So Raven' theme and people are freaking out about it: Best memes & tweetsOctober 7, 2022 | marketscreener.comPortage Biotech : NOTICE OF ANNUAL GENERAL MEETING - Form 6-K - Marketscreener.comAugust 5, 2022 | msn.comThe Impressions star Sam Gooden dies aged 87July 16, 2022 | thestreet.comCramer's Top Stock Picks: BMY NDLS NFLX MDVN SGEN BMRNMay 31, 2022 | thestreet.comThe 5 Dumbest Things on Wall Street This Week: Aug. 3March 24, 2022 | benzinga.comOption Alert: MDVN 4,950 Jul $65 Call @Bid @$0.30 - Benzinga - BenzingaSee More Headlines Receive MDVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (MDVN) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2016Today5/01/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:MDVN CUSIP58501N10 CIK1011835 Webwww.medivation.com Phone+1-415-5433470FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report MDVN Stock Analysis - Frequently Asked Questions How were (MDVN)'s earnings last quarter? (MDVN) (NASDAQ:MDVN) announced its quarterly earnings data on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.02. The biopharmaceutical company earned $206 million during the quarter, compared to analyst estimates of $214.52 million. The firm's revenue was up 17.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.58 earnings per share. What other stocks do shareholders of (MDVN) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (MDVN) investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and This page (NASDAQ:MDVN) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Report#1 election stockPorter & Company😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBiden out June 13; Kamala won’t replace him?Paradigm Press4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (MDVN) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
